{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:13Z","timestamp":1791235333079,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent venous and\/or arterial thrombosis. It is frequently associated with systemic lupus erythematosus, and thrombocytopenia is a common manifestation. This study aimed to compare patients with APS, with and without thrombocytopenia, and to describe management and outcomes of severe thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective single-centre study that included 432 patients with APS. Patients were divided into three groups according to the platelet count nadir: severe thrombocytopenia (&lt; 50\u2009G\/L), moderate thrombocytopenia (between 50 and 130\u2009G\/L) and no thrombocytopenia (\u2265 130\u2009G\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>142 patients developed thrombocytopenia during follow-up (32.9%): 57 (13%) had severe thrombocytopenia (&lt; 50\u2009G\/L) and 85 (19.4%) had moderate thrombocytopenia (50\u2013130\u2009G\/L). Patients with thrombocytopenia more frequently experienced thrombotic manifestations, including lower limb deep vein thrombosis (49% vs 37%, p=0.014), coronary thrombosis (15% vs 6.6%, p=0.006) and catastrophic antiphospholipid syndrome (CAPS) (27% vs 2.1%, p&lt;0.001). Thrombocytopenia was more frequently associated with pre-eclampsia (16.8% vs 3.7%, p&lt;0.001) and other APS manifestations, including skin (ulcer 4.9% vs 1.4%, p=0.046, cutaneous necrosis 7% vs 0.7%, p&lt;0.001), cardiovascular (MINOCA 7% vs 0.7%, p&lt;0.001, valvular disease 19.7% vs 9.3%, p=0.002), renal (18.3% vs 3.1%, p&lt;0.001) and pulmonary (5.6% vs 1%, p=0.007) manifestations. Aetiologies of severe thrombocytopenia were mainly immune thrombocytopenia (ITP) and CAPS. In patients with severe thrombocytopenia, treatment followed the approach used for primary ITP, and anticoagulation was generally maintained even in the presence of bleeding episodes. Overall survival was poorer in patients with severe thrombocytopenia (p&lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that thrombocytopenia is associated with a more severe APS phenotype and increased mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006504","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:15:20Z","timestamp":1775751320000},"page":"e006504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients"],"prefix":"10.1136","volume":"12","author":[{"given":"Carine","family":"Schmidt","sequence":"first","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-9473","authenticated-orcid":false,"given":"Matthias","family":"Papo","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Ta\u00efeb","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Lhote","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hi\u00e9","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Pha","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Cohen-Aubart","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"Cariou","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Ait Abdallah","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-6528","authenticated-orcid":false,"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Moyon","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de M\u00e9decine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026040909151305000_12.2.e006504.1","first-page":"174","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus (Los Angel)"},{"key":"2026040909151305000_12.2.e006504.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"2026040909151305000_12.2.e006504.3","first-page":"24","article-title":"Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment","volume":"147 Suppl 1","author":"Galli","year":"1996","journal-title":"Ann Med Interne (Paris)"},{"key":"2026040909151305000_12.2.e006504.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.03.005"},{"key":"2026040909151305000_12.2.e006504.5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.46497\/ArchRheumatol.2022.9088","article-title":"Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: relation to clinical, laboratory manifestations and damage index","volume":"37","author":"Gamal","year":"2022","journal-title":"Arch Rheumatol"},{"key":"2026040909151305000_12.2.e006504.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac264"},{"key":"2026040909151305000_12.2.e006504.7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/keab475","article-title":"Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study","volume":"61","author":"Pardos-Gea","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026040909151305000_12.2.e006504.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2005.10.005"},{"key":"2026040909151305000_12.2.e006504.9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2020.01.017","article-title":"Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?","volume":"74","author":"Yelnik","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026040909151305000_12.2.e006504.10","doi-asserted-by":"crossref","first-page":"103417","DOI":"10.1016\/j.autrev.2023.103417","article-title":"Thrombocytopenia in antiphospholipid syndrome: is anticoagulation and\/or antiaggregation always required?","volume":"23","author":"Zuily","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026040909151305000_12.2.e006504.11","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"2026040909151305000_12.2.e006504.12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The Epidemiology of Antiphospholipid Syndrome: A Population\u2010Based Study","volume":"71","author":"Duarte\u2010Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026040909151305000_12.2.e006504.13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683416"},{"key":"2026040909151305000_12.2.e006504.14","doi-asserted-by":"crossref","first-page":"100827","DOI":"10.1016\/j.blre.2021.100827","article-title":"Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update","volume":"49","author":"Jaime-P\u00e9rez","year":"2021","journal-title":"Blood Rev"},{"key":"2026040909151305000_12.2.e006504.15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.lpm.2016.07.023","article-title":"Syndrome catastrophique des antiphospholipides (CAPS): revue 2016","volume":"45","author":"Costedoat-Chalumeau","year":"2016","journal-title":"La Presse M\u00e9dicale"},{"key":"2026040909151305000_12.2.e006504.16","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12813"},{"key":"2026040909151305000_12.2.e006504.17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2022.11.008","article-title":"Risk of thrombosis associated with antiphospholipid antibodies in immune thrombocytopenic purpura: a single-center retrospective study of 152 patients","volume":"221","author":"Fayard","year":"2023","journal-title":"Thromb Res"},{"key":"2026040909151305000_12.2.e006504.18","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.jaut.2019.06.003","article-title":"CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission","volume":"103","author":"Pineton de Chambrun","year":"2019","journal-title":"J Autoimmun"},{"key":"2026040909151305000_12.2.e006504.19","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.chest.2019.11.010","article-title":"In-hospital mortality-associated factors in patients with thrombotic antiphospholipid syndrome requiring ICU admission","volume":"157","author":"Pineton de Chambrun","year":"2020","journal-title":"Chest"},{"key":"2026040909151305000_12.2.e006504.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010"},{"key":"2026040909151305000_12.2.e006504.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.33340"},{"key":"2026040909151305000_12.2.e006504.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu307"},{"key":"2026040909151305000_12.2.e006504.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes388"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:15:22Z","timestamp":1775751322000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006504"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006504","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}